C4 Therapeutics to Participate in BMO BioPharma Spotlight Series

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) announced its participation in the BMO BioPharma Spotlight Series on February 18, 2021, at 10:30 a.m. ET. The panel discussion, titled “Ligating” Competitors for Collaboration in the Protein Degradation Space, will focus on next-generation technologies in protein degradation. A recording will be available for replay four hours post-event on the company’s website, archived for at least two weeks. C4T specializes in small-molecule medicines targeting disease-causing proteins, offering improved treatment options for cancer and neurodegenerative diseases.

WATERTOWN, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the BMO BioPharma Spotlight Series: Proteins – Degraders and Other Next Gen Technologies, including a panel discussion, “Ligating” Competitors for Collaboration in the Protein Degradation Space, on Thursday, February 18, 2021 at 10:30 a.m. ET.

A recording of the panel discussion will be available for replay four hours following the conclusion of the event and can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. The replay will be archived on the C4T website for at least two weeks following the presentation.

About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.

FAQ

What event will C4 Therapeutics participate in on February 18, 2021?

C4 Therapeutics will participate in the BMO BioPharma Spotlight Series focusing on protein degraders.

What is the topic of the panel discussion by C4 Therapeutics?

The panel discussion is titled “Ligating” Competitors for Collaboration in the Protein Degradation Space.

When will the panel discussion by C4 Therapeutics be held?

The panel discussion will be held on February 18, 2021, at 10:30 a.m. ET.

How can I access the recording of C4 Therapeutics' panel discussion?

The recording will be available for replay four hours after the event on C4 Therapeutics' website.

How long will the panel discussion recording be available?

The replay will be archived on the company’s website for at least two weeks.